Drug · CHEMBL654
MIRTAZAPINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. MIRTAZAPINE. Drugs and targets, record CHEMBL654. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL654
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- 6-azamianserin, Avanza, Mirataz, Mirtazapin, Mirtazapina, Mirtazapine anhydrous, Norset, ORG 3770, ORG-3770, Promyrtil, Rexer
- ChEMBL
- Open Targets' highest stage
- Approval, for 3 of its 41 diseases, from ATC, DailyMed, PMDA and TTD
- Open Targets
Targets5
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| ADRA2A | Adrenergic receptor alpha-2 | Adrenergic receptor alpha-2 antagonist | ANTAGONIST | https://conductscience.org/library/genes/150 |
| ADRA2B | Adrenergic receptor alpha-2 | Adrenergic receptor alpha-2 antagonist | ANTAGONIST | https://conductscience.org/library/genes/151 |
| ADRA2C | Adrenergic receptor alpha-2 | Adrenergic receptor alpha-2 antagonist | ANTAGONIST | https://conductscience.org/library/genes/152 |
| HTR2A | 5-hydroxytryptamine receptor 2A | Serotonin 2a (5-HT2a) receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/3356 |
| HTR2C | 5-hydroxytryptamine receptor 2C | Serotonin 2c (5-HT2c) receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/3358 |
Source ChEMBL
Diseases41
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 41Source Open Targets
See all 41 diseasesTrials96
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more that Open Targets linked to it is not shown, since the release's checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00590863 | Combining Medications to Enhance Depression Outcomes | Phase 4 | 665 | 2014-04-23 | mirtazapine | Its name | ClinicalTrials.gov |
| NCT02655354 | A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity | 635 | 2021-07-02 | mirtazapine | Its name | ClinicalTrials.gov | |
| NCT03921151 | 5HT2CR Balance in Brain Connectivity in Cocaine Dependence | Phase 1/2 | 90 | 2021-11-22 | mirtazapine | Its name | ClinicalTrials.gov |
| NCT00249444 | Mirtazapine for Treating Cocaine Dependent Individuals Who Also Suffer From Depression | Phase 2 | 86 | 2017-10-25 | mirtazapine | Its name | ClinicalTrials.gov |
| NCT00302107 | A Placebo-Controlled Study of Mirtazapine for PTSD | Phase 4 | 78 | 2014-11-26 | mirtazapine | Its name | ClinicalTrials.gov |
| NCT00497081 | Mirtazapine to Reduce Methamphetamine Use Among MSM With High-risk HIV Behaviors | Phase 2 | 60 | 2014-10-20 | mirtazapine | Its name | ClinicalTrials.gov |
| NCT01178671 | Combined Mirtazapine and SSRI Treatment of PTSD: A Placebo-Controlled Trial | Phase 4 | 38 | 2016-02-29 | mirtazapine | Its name | ClinicalTrials.gov |
| NCT00834197 | 15 mg Mirtazapine Orally Disintegrating Tablets, Non-Fasting | Phase 1 | 32 | 2009-08-18 | mirtazapine | Its name | ClinicalTrials.gov |
| NCT00835575 | 15 mg Mirtazapine Orally Disintegrating Tablets, Fasting | Phase 1 | 32 | 2009-08-18 | mirtazapine | Its name | ClinicalTrials.gov |
| NCT01302964 | Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders | Phase 3 | 30 | 2018-11-07 | mirtazapine | Its name | ClinicalTrials.gov |
1 to 10 of 96
See all 96 trialsComparisons in its trials18
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Intervention vs Usual Care: deaths from any cause | 6 of 265 | 3 of 370 | 635 | NCT02655354 | Trial comparisons |
| Intervention vs Usual Care: serious adverse events | 15 of 265 | 13 of 370 | 635 | NCT02655354 | Trial comparisons |
| Mirtazapine vs Placebo: Cocaine Abstinence During Last Three Weeks of Study | 5 of 42 | 9 of 44 | 86 | NCT00249444 | Trial comparisons |
| Mirtazapine vs Placebo: Depression Score on Hamilton - Depression 25 Item | 38 of 42 | 42 of 44 | 86 | NCT00249444 | Trial comparisons |
| Mirtazapine vs Placebo: serious adverse events | 2 of 42 | 0 of 44 | 86 | NCT00249444 | Trial comparisons |
| Mirtazapine vs Placebo: serious adverse events | 0 of 39 | 0 of 39 | 78 | NCT00302107 | Trial comparisons |
| Cocaine-dependent vs Non-drug Using Healthy Controls: deaths from any cause | 0 of 35 | 0 of 28 | 63 | NCT03921151 | Trial comparisons |
| Cocaine-dependent vs Non-drug Using Healthy Controls: serious adverse events | 0 of 35 | 0 of 28 | 63 | NCT03921151 | Trial comparisons |
| Active Comparator: vs Placebo Comparator:: serious adverse events | 1 of 30 | 1 of 30 | 60 | NCT00497081 | Trial comparisons |
| Quetiapine Fumarate Extended Release (Quetiapine XR) vs Quetiapine XR andMirtazapine: serious adverse events | 0 of 20 | 0 of 16 | 36 | NCT01165541 | Trial comparisons |
1 to 10 of 18
See all 18 comparisons in its trialsPapers from its trials190
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials4
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Food Cue Reactivity Task | 1 | 0 | ConductCognition |
| Go/No-Go Task | 1 | 1 | ConductCognition |
| Purchase Task | 1 | 0 | ConductCognition |
| Symbol Coding | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL654
GET https://conductscience.org/api/drugs/v1/CHEMBL654/diseases?page=2